You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The partners are validating three rapid diagnostic test prototypes prior to initiating a trial in the Democratic Republic of the Congo during March 2020.
The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.
BD will supply its diagnostics and informatics products as part of the contract with Fleming Fund to take on AMR in Asia and sub-Saharan Africa.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
At Medica, the two firms, whose tests have received WHO prequalification, said their tests were seeing high adoption rates in lower-resource nations.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
Eurobio Scientific will also develop new test kits for the T-COR 8, a real-time PCR thermocycler originally developed for the US Army.